Med Spa Semaglutide Injections: FDA Compounding Rules

What to take away

Federal rules: FDA approval and semaglutide compounding

Semaglutide is an FDA-approved prescription drug for type 2 diabetes and, separately, for chronic weight management. FDA-approved injectable semaglutide products include Ozempic and Wegovy; their approved labeling is product-specific. Its active ingredient cannot be sold legally as a bulk ingredient to med spas for general office use.

Section 503A of the Federal Food, Drug, and Cosmetic Act sets conditions for compounding for an individual patient; a prescription is not a blanket exception to those requirements. Section 503A also restricts drugs that are essentially copies of commercially available products. Its bulk-substance conditions include applicable USP/NF standards, the FDA 503A Bulk Drug Substances List pathway, or use of a substance that is a component of an FDA-approved drug. Section 503B applies separate requirements to outsourcing facilities, including its distinct 503B Bulks List.

A 503B outsourcing facility may compound larger batches under stricter current good manufacturing practice rules. FDA stated that the shortage of semaglutide injection products was resolved as of February 21, 2025, says semaglutide does not currently appear on the 503B bulks list or FDA drug shortage list, and directs users to the FDA Drug Shortages Database for the most recent status (FDA compounding policy update).

Separate from semaglutide compounding, operators should review FDA rules on injectables and devices before adding other products or devices to the spa's menu.

Before ordering a compounded product, check the FDA Drug Shortages Database for current status and confirm that the compounder meets the applicable 503A or 503B requirements. Shortage status alone does not establish that a particular compounded product may be used.

State pharmacy and medical board jurisdiction

State boards divide semaglutide oversight. The pharmacy board regulates who may compound, dispense, and label the drug, while the medical board regulates who may prescribe, delegate, and supervise administration. For example, California's relevant authorities include the Medical Board of California and the California State Board of Pharmacy; Texas's include the Texas Medical Board and the Texas State Board of Pharmacy.

For a med spa, the medical director or collaborating physician signs a standing order or patient-specific protocol. California lets a registered nurse administer semaglutide under a standardized procedure, and the physician need not be on site; relevant authorities include the Medical Board of California and the California Board of Registered Nursing. Texas permits delegation to a nurse under a physician's order, with the physician available for consultation; relevant authorities include the Texas Medical Board and the Texas Board of Nursing.

California's Business and Professions Code Section 2052 defines unlicensed practice and is the baseline many boards use to decide when a nurse or medical assistant crosses into medicine. A med spa operator must check the state board of pharmacy for compounding source requirements, because a pharmacy licensed in another state may not ship into the spa's state.

State medical board rules often require the medical director to review patient histories before the first injection. Ownership and clinical delegation are separate questions: California operators should review California med spa ownership rules before assuming an ownership structure settles who may prescribe or supervise.

To verify your own state, check the state medical board and state board of pharmacy websites. The Federation of State Medical Boards maintains a state-by-state directory at fsmb.org; verify pharmacy licensing separately with the relevant state pharmacy board.

A common enforcement action: a med spa that injects compounded semaglutide without a state-approved protocol receives a cease-and-desist order from the medical board, and the supervising physician's license is placed on probation.

Municipal and private rules that still apply

A city or county does not usually license semaglutide separately, but it may require a general health spa or body art permit if the spa adds injections. Some municipalities treat weight loss injections as a medical service that triggers zoning review for clinical use.

Private rules also bind the operator: a commercial lease may prohibit medical procedures or require landlord consent for sharps disposal. Malpractice insurers may exclude GLP-1 weight loss unless the operator lists the service and supervising physician. Accreditation bodies may require separate policies for off-label or compounded drug use.

The distinction is simple: federal and state rules decide legality, while municipal and private rules decide whether the location and insurance permit the service. A med spa can be state-compliant and still in breach of its lease or insurance policy.

What to submit when adding a GLP-1 protocol

An application for a semaglutide service usually travels to the medical board, not the pharmacy board, unless the spa compounds on site. The operator should assemble three documents:

Some state boards want the med spa's SOP for adverse events and a sample informed consent, and the medical board's online portal takes two to six weeks. A pharmacy board inquiry about the compounding source may add several weeks.

The operator should not market the service until the board confirms the protocol in writing. A team training checklist should include semaglutide-specific screening before any staff member handles a consult.

What happens if you skip state approval

The most direct result is a board order to stop the service. A state medical board can suspend or condition the supervising physician's license. If the compounding pharmacy is unlicensed in the state, the pharmacy board may report the spa to the FDA.

Adding semaglutide consults often shifts staffing patterns, and the 1099 or W-2 question for injectors becomes more urgent. A med spa that ignores these rules may lose its ability to offer any injectable service, not just semaglutide.

Common questions